Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Memorial Sloan Kettering Cancer Center
DescriptionMUC16/IL-12 armored chimeric antigen receptor (CAR) T cell immunotherapy
Molecular Target Mucin 16 (MUC16) (CA125) ; Interleukin-12 (IL-12)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationOvarian cancer
Indication DetailsTreat MUC16 positive ovarian cancer
Regulatory Designation
PartnerEureka Therapeutics Inc.;
Juno Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today